NCT06825663 · NOT YET RECRUITING
Marker of Brain Insulin Resistance in AD Prognosis
This trial is testing whether a blood biomarker tied to brain insulin resistance can predict which people with mild cognitive impairment will go on to develop Alzheimer's disease. Researchers measure a specific protein ratio in neuron-derived particles found in plasma. It is a Phase NA study, meaning it is observational research — not testing a treatment, just evaluating whether this marker has predictive value.
You may qualify if
- Men or women aged 18 to 75
- Have been treated for mild cognitive impairment at the Nancy CHRU CMRR for 1 to 2 years
- Person affiliated to a social security scheme or beneficiary of such a scheme
- Person who has received full information on the organisation of the research and has signed an informed consent form
You're excluded if
- Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
- A person who has converted to clinically proven AD. The fact that an LP to measure AD markers has been performed is not a criterion for inclusion.
- An adult unable to give consent
- Person deprived of liberty by a judicial or administrative decision
- Persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.
- Pregnant women, women in labour or breastfeeding mothers
- Persons staying in a health or social establishment for purposes other than research.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-02-13